Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: Implications for treatment

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 3, 2015, Pages 339-341

  Farhat, M R ^a,b   Mitnick, C D ^b,c   Franke, M F ^b   Kaur, D ^d   Sloutsky, A ^d   Murray, M ^b,e   Jacobson, K R ^f,g  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Critical concentration; Drug susceptibility testing; Multidrugresistant tuberculosis

Indexed keywords

CIPROFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; VALIDITY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; MICROBIAL SENSITIVITY TEST; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

CIPROFLOXACIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84923305881     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.14.0814     Document Type: Article

References (11)

1. Mitnick C D, FrankeMF, RichML, et al. Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality. PLOS ONE 2013; 8: e58664.
2. Sirgel F A, Warren RM, Streicher EM, Victor T C, van Helden P D, Böttger E C. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother 2012; 67: 1088-1093.
3. World Health Organization. Companion handbook: to the WHO guidelines for the programmatic management of drugresistant tuberculosis. WHO/HTM/TB/2014.11. Geneva, Switzerland: WHO, 2014. http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809-eng.pdf?ua=1&ua=1 Accessed December 2014.
4. Böttger E C. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin Microbiol Infect 2011; 17: 1128-1134.
5. Horne D J, Pinto LM, Arentz M, et al. Diagnostic accuracy and reproducibility of WHO-endorsed phenotypic drug susceptibility testing methods for first-line and second-line anti-tuberculosis drugs. J Clin Microbiol 2013; 51: 393-401.
6. Gillespie S H, Crook A M, McHugh T D, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014; 371: 1577-1587.
7. Peloquin C A, Hadad D J, Molino L P D, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 852-857.
8. Isaeva Y, Bukatina A, Krylova L, Nosova E, Makarova M, Moroz A. Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system. J Antimicrob Chemother 2013; 68: 2274-2281.
9. World Health Organization Stop TB Partnership. Global Laboratory Initiative Mycobacteriology Laboratory Manual. Geneva, Switzerland: WHO, 2014. gli-mycobacteriology-lab-manual-web.pdf Accessed December 2014.
10. Sulochana S, Rahman F, Paramasivan C N. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis. J Chemother 2005; 17: 169-173.
11. Jacobson K R, Tierney D B, Jeon C Y, Mitnick C D, MurrayM B. Treatment outcomes among patients with extensively drugresistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.